BioXcel Therapeutics (BTAI) said Wednesday it has started a late-stage trial evaluating BXCL501 for potential treatment of agitation in Alzheimer's disease...
US stocks were set for a higher open Wednesday, recovering from a slump in the previous session amid concerns about the COVID-19 omicron variant and...
Health care stocks were edging higher premarket Wednesday as the iShares NASDAQ Biotechnology Index (IBB) was up 0.50% and the Health Care SPDR (XLV) was...
BioXcel Therapeutics (BTAI) reported that the US Food and Drug Administration has extended the Prescription Drug User Fee Act date for its review of the...
| Address | 555 Long Wharf Drive New Haven, Connecticut 06511 |
| Phone | +1.475.238.6837 |
| Number of Employees | 18 |
| Recent SEC Filing | 01/19/2022 4 |
| President, Chief Executive Officer & Director | Vimal D. Mehta |
| Chief Financial Officer & Vice President | Richard I. Steinhart |
| Chief Scientific Officer & Senior Vice President | Frank D. Yocca |
| Chief Medical Officer & Senior Vice President | Vincent J. O'Neill |
| Price Open | $17.45 |
| Previous Close | $17.43 |
| 52 Week Range | $16.18 - 67.74 |
| Market Capitalization | $466.7 M |
| Shares Outstanding | 28.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/10/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$4.00 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -44.97% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
